Human Immunodeficiency Virus Infections Clinical Trial
Official title:
A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT
The hope of this study is to gather data and information about the tolerability and effectiveness of Lexiva versus Sustiva in patients who have have been generally underrepresented in clinical trials.
The objective of this study is to gain tolerability and efficacy data for Norvir-boosted Lexiva versus Sustiva, both used in combination with Epzicom, as components of a first-line, once daily regimen for the treatment of HIV-1 infection in a patient population that is underrepresented in US clinical research. ;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03563742 -
A Study to Determine the Safety and Efficacy of Rilpivirine in Treatment-naive Indian Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection
|
Phase 3 | |
| Completed |
NCT00294918 -
An Efficacy and Safety Trial of Serostim® in the Maintenance of the Treatment Effect Obtained During the Study of Serostim® in Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome
|
Phase 2/Phase 3 | |
| Completed |
NCT00888446 -
Safety and Immunogenicity Study of tgAAC09, an HIV Vaccine in an Adeno-associated Virus (AAV) Capsid
|
Phase 2 | |
| Completed |
NCT00262522 -
Study of Lopinavir/Ritonavir Tablets Versus Soft Gel Capsules and Once Daily Versus Twice Daily Administration, When Coadministered With Nucleoside Reverse Transcriptase Inhibitors in Antiretroviral Naive Human Immunodeficiency Virus Type 1 Infected Subjects
|
Phase 3 | |
| Completed |
NCT00294164 -
Safety and Efficacy Trial of Serostim® in the Treatment of Subjects With Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT00332306 -
Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment
|
Phase 3 | |
| Completed |
NCT02452242 -
Safety, PK and PD Study of ABX464 in Untreated HIV Patients
|
Phase 2 | |
| Active, not recruiting |
NCT00376012 -
Short Course Intermittent Regimens for the Treatment of HIV-Associated Tuberculosis
|
Phase 3 | |
| Completed |
NCT00358917 -
Study of Lopinavir/Ritonavir Tablets Comparing Once-Daily Versus Twice-Daily Administration When Coadministered With Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Antiretroviral-Experienced Human Immunodeficiency Virus Type 1 Infected Subjects
|
Phase 3 | |
| Completed |
NCT00749840 -
Attitudes and Beliefs and the Steps of HIV Care
|
N/A |